Close Menu
Home » Epic, Avera Ink Deal to Use Liquid Biopsy Platform in Clinical Studies

Epic, Avera Ink Deal to Use Liquid Biopsy Platform in Clinical Studies

Jan 28, 2016
|
staff reporter

NEW YORK (GenomeWeb) – Epic Sciences and Avera Medical announced today that they have signed a deal under which the healthcare network will use the company's circulating tumor cell (CTC)-detection and -analysis platform in upcoming clinical studies of precision cancer therapies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Jan
28
Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Feb
05
Featured Webinar

Development of a Novel Multiplex Assay: A Partnership Case Study

Sponsored by
LGC

This webinar will provide a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.

Feb
25
Featured Webinar

Long-Read Sequencing of Human Transcription Provides Insights into Metastatic Cancer

Sponsored by
Loop Genomics

This webinar will discuss a study that used long-read transcriptome sequencing to explore the distribution of isoforms in colon cancer samples and their metastasis counterparts. 

Feb
26
Featured Webinar

Transformation of the Lab to Fight Genetic Illnesses in the Amish and Mennonite Populations

Sponsored by
Autogen

This webinar will explain how the Clinic for Special Children in Strasburg, Pennsylvania, has transformed its DNA workflows to improve the diagnosis and treatment of genetic illnesses that are prevalent in the pediatric population of its community.

What's Popular?

In Cancer

  1. Myriad Genetics Seeks Supplemental Approval of HRD Test as CDx for GSK Ovarian Cancer Drug

  2. Startup BioSkryb Eyes Oncology Applications for Single-Cell DNA Sequencing

    Premium

  3. B Cell Gene Expression Profiling May Enable Cancer Immunotherapy CDx Test

    Premium

  4. Biocartis, AstraZeneca Expand Lung Cancer Biomarker Study With Master Collaboration Agreement

  5. Immunis.AI Targets Late 2020 Prostate Cancer Risk Core Assay Launch

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.